ES2163295T3 - Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. - Google Patents

Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.

Info

Publication number
ES2163295T3
ES2163295T3 ES98947694T ES98947694T ES2163295T3 ES 2163295 T3 ES2163295 T3 ES 2163295T3 ES 98947694 T ES98947694 T ES 98947694T ES 98947694 T ES98947694 T ES 98947694T ES 2163295 T3 ES2163295 T3 ES 2163295T3
Authority
ES
Spain
Prior art keywords
formula
phenyl
heteroaryl
transferasa
farnesil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98947694T
Other languages
English (en)
Inventor
Jean-Claude Arnould
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2163295T3 publication Critical patent/ES2163295T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto de fórmula (1) Ar1C(R12)R13 OAr2(CH2)p-Ar 3 Fórmula (1) en la cual Ar1 representa: R5 es hidrógeno, alquilo C1-4, fenil-alquilo C1-4, R6 es hidrógeno, alquilo C1-4, hidroxi-alquilo C1-4, halo-alquilo C1-4, dihalo-alquilo C1-4, alcoxiC1-4, alcoxi C1-4 -alquilo C1-4, sulfanil-alquilo C1-4, amino-alquilo C1-4, N-(alquil C1-4)amino-alquilo C1-4, N,N-di(alquil C1-4)amino-alquilo C1-4 o fenil-alquilo C1-4; mes0,1ó 2; R12 y R13 son independientemente hidrógeno o alquilo C1-4; Ar 2 es fenilo o heteroarilo; p es0ó 1; Ar 3 es fenilo, piridinilo, piridazinilo, pirimidilo o pirazinilo, estando sustituido el anillo en los átomos de carbono del anillo por R2 y -(CH2)nR3 y en lacualAr 3 está unido a Ar 1 C(R12)R13 CH(AR2)O por un átomo de carbono del anillo; R2 es un grupo de la fórmula (2): **fórmula** en la cual R7 es hidrógeno o alquilo C1-4, R8 es -(CH2)q-R10 en cuya fórmulaq es 0-4 y R10 es alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, hidroxi, alcoxi C1-4, carbamoílo, N-alquil C1-4carbamoílo, N,N-(dialquil C1-4)carbamoílo, alquilo C1-4, fenilo, tienilo, o alcanoil -amino C1-4, R9 es hidroxi, alcoxi C1-6, cicloalquiloxi C3-9, heterociclil-oxi, heterociclil-alcoxi C1-4 o -NH-SO2-R11 en cuya fórmula R 11 representa trifluorometilo, alquilo C1-4, fenilo, heteroarilo, aril-alquilo C1-4 o heteroarilalquilo C1-4; o R2 representa una lactona de fórmula (3) Fórmula (3) teniendo el grupo de fórmula (2) o (3) conguración L o Den el carbono quiral alfa del aminoácido libre correspondiente; n es0,1ó 2; R 3 es fenilo o heteroarilo; los anillos fenilo y heteroarilo en R3,R5,R6,R9,R11 y Ar2 están sustituidos opcionalmente de manera independiente en los átomos de carbono del anillo con hasta tres sustituyentes seleccionados de alquilo C1-4, halógeno, hidroxi, alcoxi C1-4, alcoxiC1-4-carbonilo, alcanoílo C1-4, alcanoiloxi C1-4, amino, alquilamino C1-4, di(alquil C1-4)-amino, alcanoilamino C1-4, nitro, ciano, carboxi, tiol, alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alcano C1-4-sulfonamido, N-(alquilsulfonil C1-4)-N-alquilamino C1-4, aminosulfonilo, N-(alquil C1-4)-amino-sulfonilo, N,N-di(alquil C1-4)aminosulfonilo, carbamoílo, N-(alquil C1-4)carbamoílo, N,N-(di-alquil C1-4)-carbamoílo, carbamoil-alquilo C1-4, N-(alquil C1-4)carbamoil-alquilo C1-4, N,N-(di-alquil C1-4)carbamoil-alquilo C1-4, hidroxi-alquilo C1-4 y alcoxiC1-4alquilo C1-4, y en los grupos NH del anillo (que reemplazan hidrógeno) con alquilo C1-4, alcanoílo C1-4, alquilsulfonilo C1-4, halo-alquilo C1-4, difluorometilo o trifluorometilo; o una(o) de sus sales, profármacos o solvatos farmacéuticamente aceptables.
ES98947694T 1997-10-22 1998-10-19 Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. Expired - Lifetime ES2163295T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97402505 1997-10-22
EP97402502 1997-10-22

Publications (1)

Publication Number Publication Date
ES2163295T3 true ES2163295T3 (es) 2002-01-16

Family

ID=26147905

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98947694T Expired - Lifetime ES2163295T3 (es) 1997-10-22 1998-10-19 Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.

Country Status (10)

Country Link
US (3) US6342765B1 (es)
EP (1) EP1025088B1 (es)
JP (1) JP2001524455A (es)
AT (1) ATE205195T1 (es)
AU (1) AU9453098A (es)
DE (1) DE69801590T2 (es)
DK (1) DK1025088T3 (es)
ES (1) ES2163295T3 (es)
PT (1) PT1025088E (es)
WO (1) WO1999020611A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1140858A2 (en) 1998-12-23 2001-10-10 AstraZeneca AB Arylpropenylimidazoles as farnesyl-protein transferase inhibitors
WO2001014314A1 (fr) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Derives de benzene a substituants aromatiques et procedes de preparation de ceux-ci
GB9930317D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
US6271418B1 (en) 2000-02-22 2001-08-07 Nippon Kayaku Co., Ltd. Process for preparing (hetero) aromatic substituted benzene derivatives
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
KR102268351B1 (ko) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 그의 용도
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
HUE056325T2 (hu) 2013-08-26 2022-02-28 Biontech Res And Development Inc SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4221803A (en) * 1979-05-09 1980-09-09 Recordati, S.A. Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections
FI803127L (fi) 1979-10-03 1981-04-04 Glaxo Group Ltd Heterocykliska foereningar
US4518607A (en) * 1983-07-18 1985-05-21 Syntex (U.S.A.) Inc. Male oral contraceptive N-alkylimidazole derivatives, compositions, and method of use therefor
US5298655A (en) 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US5340828A (en) 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5238922A (en) 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5352705A (en) 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5326773A (en) 1992-10-29 1994-07-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2122795A (en) 1994-03-15 1995-10-03 Eisai Co. Ltd. Isoprenyl transferase inhibitors
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5478934A (en) 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
US5534537A (en) * 1995-03-29 1996-07-09 Merck & Co., Inc. Prodrugs of inhibitors of farnesyl-protein transferase
WO1996030015A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
ZA969273B (en) * 1995-11-06 1998-05-05 Univ Pittsburgh Inhibitors of protein isoprenyl transferases.
US6414145B1 (en) 1997-01-29 2002-07-02 Zeneca Limited Imidazolyl compounds as inhibitors of farnesyl-protein tranferase

Also Published As

Publication number Publication date
US20020058665A1 (en) 2002-05-16
ATE205195T1 (de) 2001-09-15
EP1025088B1 (en) 2001-09-05
JP2001524455A (ja) 2001-12-04
US6342765B1 (en) 2002-01-29
AU9453098A (en) 1999-05-10
PT1025088E (pt) 2002-01-30
DE69801590T2 (de) 2002-07-11
DK1025088T3 (da) 2001-11-12
US20020052376A1 (en) 2002-05-02
WO1999020611A1 (en) 1999-04-29
EP1025088A1 (en) 2000-08-09
DE69801590D1 (de) 2001-10-11

Similar Documents

Publication Publication Date Title
ES2163295T3 (es) Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BRPI9608082A (pt) derivado de quinazolina, sal de cloridreto do mesmo, e, composição farmacêutica
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
BR0010520A (pt) Novos compostos farmaceuticamente ativos
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
NO913750D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
ME00459B (me) Aril fuzirana azapoliciklična jedinjenja
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
ES2138594T3 (es) Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE374366T1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
FR2618435B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
MY105852A (en) New 2-methoxycarbonyl substituted n, n'' -di- (trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1025088

Country of ref document: ES